Viable prostate cancer was detected on histologic examination of the surgical specimen from about half of patients who underwent radical cystoprostatectomy for nonprostate cancer-related disease after having received definitive radiation therapy for localized prostate cancer.
Laparoscopic radical prostatectomy for clinically localized prostate cancer is associated with very good long-term oncologic control.
An investigational gonadotropin-releasing hormone blocker produces an almost immediate reduction in the testosterone levels of patients undergoing treatment for prostate cancer.
In a trial of alpha-blocker therapy for men with newly diagnosed chronic prostatitis/chronic pelvic pain syndrome, placebo and treatment groups had the same proportion of responders: 49 percent.
A disproportionate influence of fat mass accounts for the relationship between body mass index and lower urinary tract symptoms.
Medicolegal issues in urology, discusses the impact of medical errors on the health care system and lists several goals designed to ensure your patients' safety.
Studies suggest that diet can have a significant impact on the incidence, progression, and mortality of prostate cancer.
Successfully orienting and retaining a new physician in your practice.
Young men diagnosed with prostate cancer are more likely to have aggressive disease and better progression-free survival than older men.
There are no high-level data to support current screening practices for PSA in men of any age, particularly in older men with a shorter life expectancy.
A wide array of novel targeted prostate cancer therapies are in progress or planned for the very near future.
Men who receive some form of radiotherapy for localized prostate cancer have an elevated risk of later developing bladder and rectal cancers.
Bone mineral density may increase by 6 percent or more after 1 year of bisphosphonate treatment in men who receive the therapy soon after hormone deprivation therapy is initiated and in men who have been on the therapy for a year or longer.
Research points back to the prostate as a pain generator at a time when the field has been looking away from the end organ for the pathophysiology of chronic prostatitis/chronic pelvic pain syndrome.
Long-term treatment with finasteride resulted in consistent, clinically significant reductions in total prostate volume regardless of baseline volume.
Investigators compared specific physical therapy against general, full-body, Western-style massage in men and women with interstitial cystitis/chronic pelvic pain syndrome and men with chronic prostatitis/chronic pelvic pain syndrome.
A single injection of a bacterial protoxin activated by prostate-specific antigen led to greater than 50 percent improvement in symptoms within 3 months in a preliminary clinical study of men with benign prostatic hyperplasia.
Despite a 2-year-old advisory by AUA and two leading ophthalmology groups concerning a possible complication of cataract surgery in men taking tamsulosin, awareness of the problem has failed to reach many prescribers and patients
Men facing treatment for benign prostatic hyperplasia can expect similar outcomes after transurethral resection of the prostate or photoselective vaporization of the prostate.
Urologists John D. McConnell, MD, and Eric A. Klein, MD, have been appointed to new posts at Wake Forest and Cleveland Clinic, respectively.
The FDA has cleared for marketing a test that can help health care professionals determine the type of cancer cells present in a malignant tumor.
Patient demand for online or e-medicine prescribing appears to be growing and, along with it, concerns about the safety of prescribing over the Internet. A new study from the University of Utah, Salt Lake City, and others has revealed some surprising findings about the safety of online prescribing.
Researchers at the University of Wisconsin School of Medicine and Public Health in Madison have pinpointed a gene behavior that could mark susceptibility to prostate cancer.
Men with early prostate cancer who undergo radical prostatectomy have a lower rate of death from prostate cancer than do men who undergo watchful waiting, according to a study published in the Journal of the National Cancer Institute (2008: 100:1144-54).
Giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses to, and fewer side effects than, the more common dosing method, which is not well tolerated by many patients, according to a study by researchers at the National Cancer Institute.
New Products & Services
Research presented on advanced prostate cancer gives urologists information they can use now in daily practice and highlights an important step forward in the development of vaccine therapy.
Studies in urinary tract infections provided the foundation for rapid diagnosis of common urinary tract infection pathogens and opened windows into the mechanisms underlying chronic prostatitis and interstitial cystitis, two diseases characterized by their resistance to treatment.
Long-term results from Southwest Oncology Group trial S8949 confirm the original study finding that performing palliative debulking surgery prior to starting systemic therapy with interferon alfa-2b confers a survival benefit in patients with advanced renal cell carcinoma.